Home  |  Contact

UniProtKB/Swiss-Prot P82251: Variant p.Gly105Arg

b(0,+)-type amino acid transporter 1
Gene: SLC7A9
Variant information

Variant position:  105
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Arginine (R) at position 105 (G105R, p.Gly105Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Cystinuria (CSNU) [MIM:220100]: An autosomal disorder characterized by impaired epithelial cell transport of cystine and dibasic amino acids (lysine, ornithine, and arginine) in the proximal renal tubule and gastrointestinal tract. The impaired renal reabsorption of cystine and its low solubility causes the formation of calculi in the urinary tract, resulting in obstructive uropathy, pyelonephritis, and, rarely, renal failure. {ECO:0000269|PubMed:10471498, ECO:0000269|PubMed:11157794, ECO:0000269|PubMed:12234283, ECO:0000269|PubMed:12371955, ECO:0000269|PubMed:12820697, ECO:0000269|PubMed:15635077, ECO:0000269|PubMed:16138908, ECO:0000269|PubMed:16609684, ECO:0000269|PubMed:18752446, ECO:0000269|PubMed:19782624}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In CSNU; type III; severe loss of amino acid transport activity.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  105
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  487
The length of the canonical sequence.

Location on the sequence:   ELGTMITKSGGEYPYLMEAY  G PIPAYLFSWASLIVIKPTSF
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ELGTMITKSGGEYPYLMEAYGPIPAYLFSWASLIVIKPTSF

Mouse                         ELGTMITKSGGEYPYLMEAFGPIPAYLFSWTSLIVMKPSSF

Rat                           ELGTMITKSGGEYPYLMEAFGPIPAYLFSWTSLIVMKPSSF

Rabbit                        ELGTMITKSGGEYPYLMEAFGPIPAYLFSWSSLLVMKPSSF

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 487 b(0,+)-type amino acid transporter 1
Transmembrane 100 – 120 Helical


Literature citations

Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (b0,+AT) of rBAT.
Feliubadalo L.; Font M.; Purroy J.; Rousaud F.; Estivill X.; Nunes V.; Golomb E.; Centola M.; Aksentijevich I.; Kreiss Y.; Goldman B.; Pras M.; Kastner D.L.; Pras E.; Gasparini P.; Bisceglia L.; Beccia E.; Gallucci M.; De Sanctis L.; Ponzone A.; Rizzoni G.F.; Zelante L.; Bassi M.T.; George A.L. Jr.; Manzoni M.; De Grandi A.; Riboni M.; Endsley J.K.; Ballabio A.; Borsani G.; Reig N.; Fernandez E.; Estevez R.; Pineda M.; Torrents D.; Camps M.; Lloberas J.; Zorzano A.; Palacin M.;
Nat. Genet. 23:52-57(1999)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS CSNU ARG-105; MET-170; THR-182; ARG-195 AND ARG-259; CHARACTERIZATION OF VARIANT CSNU MET-170; FUNCTION; TISSUE SPECIFICITY;

Functional analysis of mutations in SLC7A9, and genotype-phenotype correlation in non-type I cystinuria.
Font M.; Feliubadalo L.; Estivill X.; Nunes V.; Golomb E.; Kreiss Y.; Pras E.; Bisceglia L.; d'Adamo A.P.; Zelante L.; Gasparini P.; Bassi M.T.; George A.L. Jr.; Manzoni M.; Riboni M.; Ballabio A.; Borsani G.; Reig N.; Fernandez E.; Zorzano A.; Bertran J.; Palacin M.;
Hum. Mol. Genet. 10:305-316(2001)
Cited for: VARIANTS CSNU ARG-10 DEL; LEU-52; ARG-63; LEU-69; VAL-70; ARG-105; MET-123; THR-126; ALA-158 INS; MET-170; THR-182; PHE-187; ILE-193 INS; ARG-195; ARG-230; THR-241; GLU-244 DEL; ARG-259; TRP-333; THR-354; ARG-379 AND THR-382; CHARACTERIZATION OF VARIANTS CSNU VAL-70; ARG-105; MET-170; THR-182; TRP-333 AND THR-354;

Cystinuria in children: distribution and frequencies of mutations in the SLC3A1 and SLC7A9 genes.
Botzenhart E.; Vester U.; Schmidt C.; Hesse A.; Halber M.; Wagner C.; Lang F.; Hoyer P.; Zerres K.; Eggermann T.;
Kidney Int. 62:1136-1142(2002)
Cited for: VARIANTS CSNU ARG-105; VAL-224 AND VAL-331;

Molecular genetic analysis of SLC3A1 and SLC7A9 genes in Czech and Slovak cystinuric patients.
Skopkova Z.; Hrabincova E.; Stastna S.; Kozak L.; Adam T.;
Ann. Hum. Genet. 69:501-507(2005)
Cited for: VARIANTS CSNU ARG-105; MET-123; ARG-319 AND TRP-333;

Large rearrangements detected by MLPA, point mutations, and survey of the frequency of mutations within the SLC3A1 and SLC7A9 genes in a cohort of 172 cystinuric Italian patients.
Bisceglia L.; Fischetti L.; Bonis P.D.; Palumbo O.; Augello B.; Stanziale P.; Carella M.; Zelante L.;
Mol. Genet. Metab. 99:42-52(2010)
Cited for: VARIANTS CSNU ARG-105; GLU-105; MET-123; THR-182 AND LYS-250;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.